New products and the successful addition of Boots' former Nurofen business helped operating profits at Reckitt Benckiser jump 13 per cent yesterday.
The household products group, which makes Airwick, Vanish and Cillit Bang, said second quarter revenues rose by 17 per cent at constant exchange rates to £1.22 billion, lifting underlying profits for the period to £213 million.
The performance between April and June included revenues of £127 million from Boots Healthcare International - the business which Reckitt acquired for £1.93 billion in February. The contribution from the business, which makes Strepsils, Clearasil and Nurofen, had been ahead of expectations, it added.
Chief executive Bart Becht said a declining rate of growth in Europe had been offset by strong performances elsewhere.
"It's clear that in the European markets growth has come down," he said.
"But we believe, based on the strength of the business in North America and developing markets, we can stick with our net revenue forecast for the full-year and that, combined with the stronger margin, leads us to believe we can upgrade the profit forecast."
Reckitt, which has its UK headquarters in Slough and offices in Swindon and Hull, said the strong first half showing encouraged it to forecast full-year revenues growth of around 15 per cent at constant exchange rates.
Mr Becht said much of the success was due to new products such as Vanish Oxi Action, Airwick Freshmatic and dishwasher product Finish 5in1.
Further launches are planned for the second half of the year, including Gaviscon Double Action to treat both heartburn and indigestion and Clearasil Ultra, which is being rolled out globally following its initial launch in North America in 2005.
Last month, Reckitt lost out to Johnson & Johnson in a £8.6 billion bidding war for Pfizer's consumer healthcare business.
Mr Becht said the company is not looking "intensively" at alternative acquisitions at this time but will continue to monitor "interesting opportunities".
Shares closed down 20p at 2056p.